Multiple Sclerosis Drug Sales Will Reach $23.2bn In 2020, New Visiongain Analysis Predicts

06 September 2018
Pharma

A new report forecasts that the global multiple sclerosis drugs market will generate $23.2 billion in 2020. That revenue forecast and others appear in Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026: Revenue Forecasts for Leading Submarkets including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif, published by visiongain in June 2016. That company is a business information publisher and consultancy based in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), and 2.5 million people around the world suffer from the condition. MS represents a lucrative pharmaceutical market, with a range of blockbuster therapies that are able to charge premium prices.”

“However, most of these leading therapies will face patent expiry within the next ten years, representing a crucial period for this market, and it remains to be seen whether it can maintain growth in the face of generic and biosimilar competition. Fortunately, for the market and for patients, the drugs pipeline contains many exciting therapies which could represent future blockbusters and market leaders.”

Visiongain’s new report shows revenue forecasts to 2026 for 10 leading marketed drugs and three promising candidates in the R&D pipeline:

• Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
• Tecfidera (dimethyl fumarate) by Biogen
• Avonex (interferon beta-1a) by Biogen
• Gilenya (fingolimod) by Novartis
• Rebif (interferon beta-1a) by Merck KGaA
• Tysabri (natalizumab) by Biogen
• Betaseron/Betaferon (interferon beta-1b) by Bayer
• Aubagio (teriflunomide) by Sanofi
• Plegridy (peginterferon beta-1a) by Biogen
• Lemtrada (alemtuzumab) by Sanofi
• Ocrelizumab (Ocrevus / RG1594) by Roche
• Ozanimod by Celgene
• Zinbryta (daclizumab high-yield process) by Biogen and AbbVie.

Visiongain’s study also gives revenue predictions to 2026 for five therapeutic submarkets:

• Monoclonal antibodies (mAbs)
• S1PR modulators
• Interferons
• Other immunomodulators
• Other agents.

That multilevel investigation also shows revenue forecasts to 2026 for 10 leading national markets for multiple sclerosis drugs:

• US
• Japan
• Canada
• Germany, France, UK, Italy and Spain
• India and China.

Visiongain’s new report discusses trends that will stimulate sales expansion over the next ten years, as well as forces that will limit revenues. Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026 adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever